A key component of BioNTech’s commercial strategy is to collaborate with partners that have a similar drive and commitment in developing and commercializing truly innovative and disruptive immunotherapies.
BioNTech is actively engaged in many collaborations, partnerships and licensing deals supporting development of first-in-class therapies. The Company also benefits from a global network of academic partners, which we leverage for leading clinical guidance, scientific expertise and novel ideas, the latter of which we translate, in collaboration with our partners, into successful commercial products.
BioNTech has pharma collaborations in each of our therapeutic businesses. Our current partnerships are a testament to our ability to innovate and execute.
To learn more about partnering, licensing, collaborations, partnerships, or for any scientific inquiries, please contact:
An der Goldgrube 12